Kinase inhibitor of Bcr-abl and Src authorized to treat chronic myeloid
Kinase inhibitor of Bcr-abl and Src authorized to treat chronic myeloid leukemia (CML) [17]. Because Src is definitely an oncoprotein closely connected with strong tumor proliferation and invasion [18], dasatinib…